Sputnik V developers offer their technologies to European companies
11:13, 11 December 2020
Photo: Cover Images/Global Look Press
The developers of the Russian Sputnik V coronavirus vaccine have expressed readiness to share their technologies with the French pharmaceutical corporation Sanofi and the British company GlaxoSmithKline.
Sputnik V is willing to share its technology with Sanofi and GSK to help in developing their next vaccine. A partnership of different producers is the way of the future. Together we are stronger, Sputnik V tweeted.
#SputnikV is willing to share its technology with Sanofi @sanofi and GSK @GSK to help in developing their next vaccine. A partnership of different producers is the way of the future. Together we are stronger.https://t.co/20CImXAFow
The proposal comes in response to news that an experimental COVID vaccine from Sanofi and GSK proved insufficient immune response in clinical trials. Both companies said they plan to launch another study next year, hoping to develop a more effective vaccine by the end of 2021.
NEWS.ru reported earlier that production of vaccines against coronavirus for foreign countries would start at sites abroad, Russian Presidential Spokesman Dmitry Peskov said.